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SUMMARY
Despite the histological similarity of ependymomas from throughout the neuroaxis, the disease likely
comprises multiple independent entities, each with a distinct molecular pathogenesis. Transcriptional
profiling of two large independent cohorts of ependymoma reveals the existence of two demographically,
transcriptionally, genetically, and clinically distinct groups of posterior fossa (PF) ependymomas. Group A
patients are younger, have laterally located tumors with a balanced genome, and are much more likely to
exhibit recurrence, metastasis at recurrence, and death compared with Group B patients. Identification
and optimization of immunohistochemical (IHC) markers for PF ependymoma subgroups allowed validation
of our findings on a third independent cohort, using a human ependymoma tissue microarray, and provides
a tool for prospective prognostication and stratification of PF ependymoma patients.
Significance
Despite current therapy for ependymoma, consisting of maximal safe resection and radiotherapy, mortality rates remain as
high as 45%. Chemotherapeutic regimens have been proven largely ineffective in clinical trials. Development of targeted
therapy requires an in-depth understanding of the pathogenesis of the disease, including the heterogeneity between tumors.
We identify two molecularly and clinically distinct sets of PF ependymomas, and markers to differentiate them. Subgroup
identification should influence theaggressivenessof current treatments forPFependymomapatients andallow for theappro-
priate stratification of future clinical trials of PF ependymoma. A single targeted therapy is unlikely to be effective in the two
highly disparate subgroups of PF ependymoma, and future investigations should not consider them as a single disease.
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INTRODUCTION
Ependymoma is the third most common brain tumor in children,
and remains incurable in up to 45% of patients (Korshunov
et al., 2010; Merchant et al., 2009). It arises throughout the
neuroaxis, including the supratentorial brain (comprising the
cerebral hemispheres), the posterior fossa (encompassing
the cerebellum and brainstem), and in the spinal cord including
the filum terminale (Louis et al., 2007). Both adults and children
are affected, with posterior fossa tumors occurring more com-
monly in children and supratentorial and spinal tumors domi-
nating in adulthood (Kilday et al., 2009). Clinical behavior is
highly variable, with subsets of patients experiencing a rapidly
fatal clinical course and others harboring relatively slow-
growing variants capable of recurring up to 20 years after
primary treatment (Bouffet et al., 1998; Grill et al., 2001; Kor-
shunov et al., 2010). Current best clinical management of
ependymoma includes maximal safe surgical resection fol-
lowed by adjuvant radiotherapy (Kilday et al., 2009). No chemo-
therapeutic regimen has demonstrated a clear overall survival
benefit in clinical trials for ependymoma. As a result, current
five-year survival rates range from 39% to 64%, with five-year
event-free survival rates of 23% to 45% (Zacharoulis et al.,
2007). Attempts to develop targeted therapies for ependymoma
have been hampered by the relative paucity of cell lines, xeno-
grafts, or animal models of the disease compared with other
intracranial neoplasms.
In spite of histopathological similarities, ependymomas are
very heterogeneous tumors with disparate mRNA expression
profiles, supporting the hypothesis that the histological entity
‘‘ependymoma’’ in fact comprises a group of related diseases
(Taylor et al., 2005; Johnson et al., 2010). The genetic land-
scape of ependymoma is also heterogeneous, with subsets
of tumors exhibiting frequent gross numerical chromosomal
alterations and others displaying only single focal aberrations,
or even a balanced genome. A recurrent observation in
several tumor cohorts is that up to 50% of posterior fossa
cases have balanced genomic profiles (Johnson et al., 2010;
Korshunov et al., 2010; Mendrzyk et al., 2006; Dyer et al.,
2002; Carter et al., 2002). A molecular model for prognostica-
tion of pediatric and adult ependymomas was recently pub-
lished based upon tumors with specific genomic aberrations,
or the absence of copy number alterations (Korshunov et al.,
2010).
Further addressing the genetic heterogeneity of ependy-
moma, Johnson et al. reported a comprehensive study cata-
loguing DNA copy-number alterations in subgroups of ependy-
moma defined by messenger RNA (mRNA) and microRNA
(miRNA) profiles (Johnson et al., 2010). Remarkably, they gener-
ated a mouse model of supratentorial ependymoma and present
supporting evidence that the cell-of-origin for supratentorial
ependymoma resides in the radial glial lineage (Johnson et al.,
2010; Taylor et al., 2005). Evidence for a molecular ‘‘driver’’ alter-
ation and a cell-of-origin for posterior fossa ependymoma is
still lacking. We have now applied genomic methodologies to
three independent cohorts of human ependymomas to uncover
the extent of intertumoral molecular heterogeneity and the
nature of the clinically relevant subgroups of posterior fossa
ependymoma.
RESULTS
Consensus Clustering Identifies Three Principal
Molecular Subgroups of Ependymoma
Gene expression profiles were generated from two non-overlap-
ping cohorts of WHO grade II and III ependymomas. One-
hundred-two sampleswere analyzed in Toronto on theAffymetrix
Exon 1.0ST array (Santa Clara, CA), and 75 samples were
analyzed in Heidelberg on the Agilent two-color 4x44K microar-
ray (SantaClara,CA). Basedupon themedian absolute deviation,
the 1000 most varying genes in each dataset were used to
perform consensus hierarchical clustering (HCL) from 2 to 10
subgroups (Figure 1A; see Figure S1A available online) (Monti
et al., 2003). Despite varying the initial number of input genes,
we consistently found three large and stable clusters in both
independent datasets that were generated using distinct tech-
nologies (Figure 1B; Figures S1B and S1C). The Toronto cohort
(n = 102) was divided into 3 subgroups of 31 (31%) largely supra-
tentorial (ST), 39 (38%) largely posterior fossa (PF), and 32 (31%)
spinal and posterior fossa (SP+PF) tumors, whereas the Heidel-
berg cohort (n = 75) was divided into 3 subgroups of 28 (37%)
(ST), 18 (24%) (PF), and 29 (39%) (SP+PF) tumors (Table 1;
Figures S1D–S1F).
In addition, we performed consensus clustering using non-
negative matrix factorization (NMF) (Brunet et al., 2004) and
determined that both HCL and NMF subgroup assignments
were highly concordant (Figure 1C; Rand index: Toronto =
0.96, Heidelberg = 0.85, p < 0.0001). Using SigClust (Liu et al.,
2008), we performed all pairwise comparisons between HCL-
defined subgroups and determined that all three subgroups
were statistically significant (Figure 1D). Silhouette analysis
(Rousseeuw, 1987) demonstrated that 96% of samples in the
Toronto and Heidelberg datasets had positive silhouettes and
thus were representative of their cluster assignments (Figure 1E).
As performed previously (Verhaak et al., 2010), samples with
positive silhouettes were defined as ‘‘core samples,’’ and
7/177 (4%) samples exhibiting negative silhouettes were
removed from subsequent analyses. Therefore, using both
consensus HCL and NMF, we found 3 principal subgroups of
ependymoma divided largely according to their anatomical
location into ependymomas arising from: (1) The ST, (2) the PF,
and (3) PF+SP tumors (Table 1; Figure S1E).
We next asked whether the same sets of genes defined the
same three subgroups in both independent datasets. To this
end, we identified common subtypes across the two datasets
by Subclass mapping, and confirmed that the subgroups identi-
fied in both datasets were nearly identical (Figure 1F) (Hoshida
et al., 2007). Furthermore, we demonstrated that the subgroups
were derived from distinct anatomical locations, a finding largely
consistent with our prior publication (Taylor et al., 2005). We
conclude that there are three transcriptionally defined principal
subgroups of ependymoma, and that a subset of posterior fossa
ependymomas is more similar to spinal tumors.
Identification of Two Molecularly and Clinically Distinct
Groups of Posterior Fossa Ependymoma
Principal component analysis with the same 1000 most varying
genes in each dataset robustly demonstrates two distinct sub-
groups of PF ependymoma (Figure 2A). The group comprised
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purely of PF ependymomas was designated Group A, whereas
PF tumors that clustered with spinal ependymomas in the
previous analysis (PF+SP) were designated Group B tumors
(Figures 1B and 1C). The 100 most influential genes discrimi-
nating the two groups were identified using the Goeman’s global
test (Goeman et al., 2004). Signature genes discriminating Group
A from Group B were highly concordant across both datasets,
as illustrated in Figure 2B.
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Figure 1. Identification of Three Primary Molecular Classes of Ependymoma
(A) Area under empirical cumulative distribution plots (k = 2 to k = 10), generated from consensus hierarchical clustering of 102 Toronto and 75 Heidelberg
samples identifies strongest statistical support for the existence of three primary subgroups of ependymoma. (k denotes the number of clusters)
(B) Consensus HCL heatmaps displaying the three robust subgroups of ependymoma defined by gene expression.
(C) Consensus NMF of 102 Toronto and 75 Heidelberg samples at k = 3 demonstrates significant concordance with the consensus HCL subgroup classification.
Significance of similarity was determined by a Rand index and permutation testing of the Toronto sample labels (see experimental procedures).
(D) Significance of HCL subgroup classifications in both datasets determined by pairwise comparisons between all clusters using SigClust.
(E) Silhouette analysis identifies ‘‘core’’ samples defined as tumors with positive silhouette values.
(F) Submap analysis demonstrates that the HCL-defined clusters identified in the Toronto cohort are nearly identical to the HCL-defined clusters defined in the
Heidelberg cohort. Significance of similarity measured by FDR-corrected p value.
See also Figure S1.
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In the Toronto and Heidelberg datasets, both independently
andcombined,GroupA tumorsarose in youngerpatients (median
age 2.5 years), whereas Group B tumors occurred predominantly
in older patients (median age 20) (Table 1 and Figure 2C, p <
0.0001, Mann-Whitney U test). Anatomically, 67% of Group A
tumors occurred laterally, whereas 95% of Group B ependymo-
mas occurred in themidline (Figure 2D, p < 0.0001, Fisher’s exact
test). Further, Group A tumors were more likely to show invasive
growth into the cerebellum on neuropathological examination
(Figure 2E, p = 0.04, Fisher’s exact test). After subgroup analysis,
detailed neuropathological re-examination of both Group A and
Group B PF ependymomas did not reveal any histological differ-
ences.Further, the frequencyofGrade II and III tumorswassimilar
(Table 1). Patients with 5 years of follow-up, harboring Group A
ependymomas, exhibited a significantly increased incidence of
recurrence (Figure 2F, p = 0.0424, Fisher’s exact test) and
mortality (Figure 2G, p = 0.0164, Fisher’s exact test). Five-year
progression-free and overall survival rates were 47% and 69%
for Group A tumors (Figure 2H, p = 0.017, log-rank test) and
79% and 95% for Group B tumors (Figure 2H, p = 0.0048, log-
rank test). Detailed clinical information for Groups A andB tumors
of the Toronto and Heidelberg cohort can be found in Table S1.
Wenext compared various clinical parameterswithinGroupsA
andB assessing the independence of age, level of resection, and
radiotherapy on patient survival. Progression-free and overall
survival of Group B patients was not prognostically significant
when comparing age (above or below 18 years), use of radio-
therapy, and level of resection (Figures S2A–S2C). For Group A
tumors, no prognostic significance was observed related to age
(Figure S2D; above or below 4 years). Group A patients who
Table 1. Overall Comparison of Three Ependymoma Subgroups and Group A and B in both Gene Expression Profiling Cohorts
Heidelberg
Subgroups
Toronto
Subgroups
Heidelberg
PF tumors
Toronto
PF tumors Both Cohorts PF Subgroups
ST PF+SP PF ST PF+SP PF Grp B Grp A Grp B Grp A ST PF+ SP PF Grp B Grp A
Number of Patients 28 29 18 31 32 39 20 18 13 34 59 61 57 33 52
Age (years)
Median 14 30 5.5 8 18 2 24 5.5 10 2 10 25 4 20 2.5
>18 12 21 2 4 16 0 13 2 3 0 27% 61% 4% 48% 4%
4-18 16 7 10 17 13 16 7 10 9 12 56% 33% 46% 48% 42%
<4 0 1 6 8 2 23 0 6 1 22 14% 5% 51% 3% 54%
Gender
Female 15 14 7 15 11 15 9 7 5 13 51% 41% 39% 42% 38%
Male 13 15 11 14 19 24 11 11 8 21 46% 56% 61% 58% 62%
Localization
Supratentorial 25 1 0 24 5 2 0 0 0 0 82% 10% 4% 0% 0%
Posterior fossa 1 20 18 4 14 36 20 18 13 34 8% 56% 95% 100% 100%
Spinal 2 8 0 1 13 1 0 0 0 0 5% 34% 2% 0% 0%
Histologic grade
WHOII 8 17 8 — — — 9 8 — — — — — — —
WHOIII 20 12 10 — — — 11 10 — — — — — — —
Level of resection
Complete 15 13 8 — — — 13 8 — — — — — — —
Incomplete 11 8 10 — — — 7 10 — — — — — — —
Radiotherapy
Yes 22 16 9 — — — 16 9 — — — — — — —
No 4 5 9 — — — 4 9 — — — — — — —
Metastasis at time of recurrence
Yes 8 3 4 — — — 3 4 — — — — — — —
No 20 26 14 — — — 17 14 — — — — — — —
Recurrence
Yes 17 7 10 — — — 5 9 — — — — — — —
No 11 22 8 — — — 15 9 — — — — — — —
Death
Yes 11 1 6 — — — 1 6 — — — — — — —
No 17 28 12 — — — 19 12 — — — — — — —
Survival probability (%)
5 year PFS 41 79 52 — — — 79 47 — — — — — — —
5 year OS 72 96 69 — — — 95 69 — — — — — — —
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received radiotherapy demonstrated an increased progression-
free survival; however, no improvement in overall survival was
observed (Figure S2E). In contrast with Group B tumors, only
Group A patients had an improved progression-free and overall
survival where gross total resection was achieved (Figure S2F).
GroupA ependymomas occurring in themidline had an improved
progression-free and overall survival compared with those
occurring laterally (Figure S2G). We conclude that the two
subgroups of PF ependymoma identified through transcriptional
profiling are bothmolecularly and clinically distinct, and that their
differences are highly clinically significant and relevant.
PF Ependymoma Subgroup-Specific Chromosomal
Aberrations
We analyzed all samples from both cohorts, studied by gene
expression profiling, for which sufficient amounts of DNA were
available (n = 152), by array comparative genomic hybridization
(aCGH) (Figure S3A). Genomic profiles of ependymoma samples
from the Heidelberg cohort have been described previously
(Korshunov et al., 2010). Group A and Group B ependymomas
were identified as outlined here previously, yielding 75 tumors
where both subgroup assignment and aCGH data were avail-
able. Group A tumors exhibited a largely balanced genomic
profile, with an increased occurrence of chromosome 1q gain
compared with Group B (Figures 3A and 3B; p = 0.0437, Fisher’s
exact test). Normal cell contamination in Group A is a less likely
explanation for the balanced genomic landscape observed
because the majority of samples were composed of tumor cells
(R80%) by hematoxylin and eosin staining (Figure S3B), and
because chromosome 1q gains, when present, were found in
the majority of cells as shown by fluorescence in situ hybridiza-
tion (FISH) (Figure S3C). Finally, we compared the copy number
intensities derived from the aCGH signals for chromosome 1q
gain, 6q loss, and 9q gain, and demonstrated that chromosomal
aberrations in Group A had similar intensities as aberrations in
Group B (Figure S3D). This is in line with previous reports that
a large proportion of PF ependymoma exhibit a balanced
genomic profile (Johnson et al., 2010; Korshunov et al., 2010;
Mendrzyk et al., 2006; Dyer et al., 2002; Carter et al., 2002). In
contrast, Group B ependymomas exhibited numerous cytoge-
netic abnormalities involving whole chromosomes or chromo-
somal arms, including loss of chromosome 1, 2, 3, 6, 8, 10,
14q, 17q, and 22q, and gain of 4, 5q, 7, 9, 11, 12, 15q, 18, 20,
and 21q (Figures 3A and 3B). Chromosomal aberrations also
classified tumors into the recently described cytogenetic risk
groups (Korshunov et al., 2010). Group A ependymomas
included predominantly high-risk groups 2 (Figure 3A; p =
0.0001, Fisher’s exact test) and 3 (p = 0.0423, Fisher’s exact
test), whereas the vast majority of Group B tumors were classi-
fied into the low-risk group 1 (p < 0.0001, Fisher’s exact test).
We conclude that PF Group A and Group B ependymomas
have distinct somatic genetic events in addition to the transcrip-
tional and clinical differences described before.
Identification of Biological Pathways and Processes
Discriminating PF Group A and PF Group B
Ependymomas
We performed Gene Set Enrichment Analysis (Subramanian
et al., 2005) to identify biological processes and signaling path-
ways distinguishing Group A from Group B ependymomas.
Gene sets were compiled from the National Cancer Institute
(NCI), Kyoto Encyclopedia of Genes and Genomes (KEGG),
Protein Families (PFAM), Biocarta, and Gene Ontology (GO)
pathway databases. Significant gene sets (FDR < 0.035, p <
0.01) were visualized as interaction networks with Cytoscape
and Enrichment Map (Figure 4; see also Figures S4A and S4B
and Table S2) (Merico et al., 2010). Group B ependymomas
were defined by gene sets involved in ciliogenesis/microtubule
assembly and mitochondria/oxidative metabolism. Group A
ependymomas were characterized by numerous cancer-related
networks, namely angiogenesis (HIF-1a signaling, VEGF
signaling, cell migration), PDGF signaling, MAPK signaling,
EGFR signaling, TGF-b signaling, integrin signaling, extracellular
matrix assembly, tyrosine-receptor kinase signaling, and RAS/
small GTPase signaling. The clear difference in active biological
pathways between Group A and Group B supports their distinct
natures and suggests possible avenues for future subgroup-
specific targeted therapies.
Validation of PF Ependymoma Subgroups
Proper validation of the two subgroups of PF ependymoma
requires the use of an orthogonal technology applied to an addi-
tional and independent cohort of ependymomas. We selected
immunohistochemistry (IHC) markers representative of each
PF subgroup, and stained a TMA comprised of a completely
non-overlapping cohort of 265 PF ependymomas. Using the
Goeman’s global test statistic (Goeman et al., 2004), subgroup
markers were selected from the transcriptional data by first
ranking genes according to their ‘‘influence score’’ in both the
Toronto and Heidelberg datasets (Figure 5A; Figure S5A). The
‘‘influence score’’ measures the degree that each gene can
distinguish between pre-defined classes or subgroups, in this
case Groups A and B. We selected the genes that showed high-
est ranks in both datasets for Groups A and Group B. Laminin
alpha-2 (LAMA2), which exhibited an increase in expression in
Group A versus Group B, was selected as a marker of Group A
(Figure 5B; p < 0.0001, unpaired t-test).Neural Epidermal Growth
Factor Like-2 (NELL2), which exhibited an increase in expression
in Group B versus Group A, was selected as amarker of Group B
(Figure 5B; p < 0.0001, unpaired t-test). To assure future routine
clinical applicability of our markers, we prioritized selection and
optimization of commercially available antibodies to LAMA2 and
NELL2 as markers of Group A and Group B PF ependymoma,
respectively (Figure 5C). We next confirmed that the gene
expression of LAMA2 and NELL2 in the Heidelberg gene expres-
sion profiling cohort were highly concordant with protein expres-
sion by IHC (Figure S5B). Ninety-four percent (17/18) of tumors
classified as Group A were positive for LAMA2, and 100%
(19/19) of tumors classified as Group B were also positive for
NELL2. We proceeded to stain our TMA validation set consisting
of 265 PF ependymomas; 32% stained positive for LAMA2 and
negative for NELL2, 52% stained positive for NELL2 and nega-
tive for LAMA2, 8% stained positive for both markers, and 8%
stained negative for both markers (Figure 5D). Detailed clinical
information on tumors staining for LAMA2 or NELL2 in the valida-
tion cohort is summarized in Table S3.
Using LAMA2 and NELL2 as markers of Groups A and B,
respectively, we next attempted to validate the predominant
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Figure 2. Transcriptome Analysis Distinguishes Two Distinct Subgroups of Posterior Fossa Ependymoma
(A) Graphical illustration of global differences between the transcriptomes of Group A and Group B PF ependymomas determined by principal component
analysis. Individual tumor samples are represented as spheres, (red = Group A, blue = Group B) and ellipsoids display two standard deviations around each
subgroup.
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pathways identified by GSEA within the TMA cohort. In Group B
we focused on the most over-represented Group B signaling
pathway: ciliogenesis and microtubule assembly. We selected
Kinesin Family Member 27 (KIF27) as an established marker of
cilia signaling in other brain neoplasms (Rink et al., 2009; Wilson
et al., 2009) and demonstrated that 91% of NELL2+/LAMA2-
tumors (hereafter Group B) stained positive, whereas 17% of
NELL2-/LAMA2+ tumors (hereafter Group A) showed a pattern
of positivity (Figures S5C and S5E). From our GSEA analysis,
extracellular matrix signaling was the most significantly enriched
Group A pathway. We therefore selected Tenascin-C (TNC),
a type of matrix glycoprotein, which has been reported to be
upregulated in pediatric ependymoma, as a marker of ECM
signaling (Puget et al., 2009; Korshunov et al., 2002). Ninety-
four percent of Group A tumors stained positive for TNC, and
only 11% of Group B tumors showed positivity (Figures S5D
and S5E). These IHC experiments provide a degree of validation
for the predominant subgroup-specific pathways identified
using GSEA.
Using FISH, we next attempted to validate themost prominent
genomic alterations identified from the Toronto and Heidelberg
aCGH dataset in the TMA cohort. We confirmed that Group B
patients frequently harbored chromosome 6q loss, 9q gain,
15q gain, 18q gain, and 22q loss, whereas Group A patients
were represented only by chromosome 1q gain (Figure 6A). Inter-
estingly, Group A patients with chromosome 1q gain, amarker of
poor outcome (Mendrzyk et al., 2006; Korshunov et al., 2010),
exhibited no difference in survival outcome compared with
Group A patients who did not possess this aberration (Fig-
ure S6C). Group A tumors were largely classified into cytoge-
netic moderate-risk group 2 and cytogenetic high-risk group 3
(Korshunov et al., 2010), whereas Group B tumors were predom-
inantly cytogenetic low-risk group 1. This provides additional
molecular evidence in a third independent cohort to support
the distinction of Group A and B tumors as defined by LAMA2
and NELL2 immunopositivity, respectively.
We also observed numerous clinical disparities between
Group A and B patients of the validation cohort consonant,
with the differences observed in the gene expression cohorts
(Table S4). Patients with Group A ependymomas were signifi-
cantly younger (median age 4 versus 39 years) (Figure 6B; p <
0.0001, Mann-Whitney U test). Patients with Group A tumors
weremore commonlymale (Figure 6C; p = 0.0076, Fisher’s exact
test) andmore frequently classified asWHOgrade III ependymo-
mas (Figure 6D; p < 0.0001, Fisher’s exact test). Patients with
Group A ependymomas had a higher incidence of metastases
at the time of recurrence and had a significantly diminished
prognosis compared with Group B patients (Figures 6E–6G;
p < 0.0001, log-rank test). Progression-free and overall survival
rates were of 24% and 48%, respectively, for Group A tumors
and 92% and 98%, respectively, for Group B tumors (Figures
6F and 6G; p < 0.0001, log-rank test). When cases stained for
both or none of the two markers, these tumors had no associa-
tion with metastasis at time of recurrence and formed two inter-
mediate patient survival groups (Figures 6E–6I). Further, 82% of
tumors that fail to stain for either LAMA2 or NELL2 are WHO III;
in contrast tumors immunopositive for both markers are equally
distributed (Figures S6A and S6B). We conclude that Group A
tumors are clinically and molecularly distinct from Group B
tumors, have a worse prognosis, and can be identified through
routine IHC staining of formalin-fixed, paraffin-embedded
sections for LAMA2 and NELL2.
A major determinant of long-term survival in ependymomas is
the extent of surgical resection, and indeed extent of resection
is an important independent variable on a Cox proportional
hazard model for the entire current cohort of PF tumors that
does not account for subgroups (Table S5 and Figure S6D)
(Bouffet et al., 1998; Merchant et al., 2004). Because Group A
ependymomas are more commonly located laterally in the
cerebellopontine angle, we questioned whether the observed
differences in outcome were secondary to a decreased inci-
dence of gross total resection. However, we found that patients
with Group B tumors, amenable to gross total resection, dis-
played a 5-year progression-free and overall survival rate of
91% and 100%, respectively, as opposed to patients with gross
totally-resected Group A tumors, who exhibited worse progres-
sion-free and overall survival rates of 18% and 52%, respec-
tively (Figures 6H and 6I; p < 0.0001, log-rank test). These
data clearly suggest that the difference in prognosis between
PF ependymoma subgroups is not solely based on a diminished
incidence of gross total resection among patients with Group A
tumors.
We next compared various clinical variables within Groups A
and B. In the case of extent of resection, prognostic relevance
was observed only in the progression-free survival of patients
with Group A tumors (Figure S6E), whereas patients with Group
B tumors exhibited no improvement in either progression-free
or overall survival regardless of gross total resection status (Fig-
ure S6F). Further, Kaplan-Meier analyses illustrate that age and
radiotherapy did not have significant prognostic value for
patients when they were stratified into Group A or B (Figures
S6G–S6J). However, a trend toward improvement in survival
was observed specifically in Group B patients who received
radiotherapy. Multivariate analysis using a Cox proportional
hazard model that included gender, extent of resection, age,
WHO grade, use of radiotherapy, NELL2 staining (Group B),
and LAMA2 staining (Group A) revealed that our histological
markers were the best independent predictors of both overall
(B) Heatmap of the top 100 most discriminating genes between Group A and Group B ependymomas, in both datasets, as calculated by Goeman’s Global
Test statistic.
(C) Box plots demonstrating the association of Group A ependymomas with younger age at diagnosis, and Group B ependymomas with older age at diagnosis.
Median age is also indicated. p-values were determined by a Mann-Whitney U test.
(D–G) Pie charts demonstrating an association of Heidelberg Group A ependymomas with lateral localization, cerebellar invasion, increased recurrence, and
death within 5 years from diagnosis compared with Group B tumors. Statistical significance of PF location and incidences of recurrence and death were
determined by Fisher’s exact test.
(H) Kaplan-Meier survival curves demonstrating a worse progression-free and overall survival in Group A versus Group B ependymomas. Statistical significance
was determined by a log-rank test.
See also Table S1 and Figure S2.
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Figure 3. Identification of Subgroup-Specific Copy Number Alterations in the Posterior Fossa Ependymoma Genome
(A) Copy number profiling of 75 PF ependymomas using 10K array-CGH identifies disparate genetic landscapes between Group A and Group B tumors. Toronto
and Heidelberg copy number datasets have been combined and summarized in a heatmap. The heatmap also displays the association of tumors to cytogenetic
risk groups 1, 2, and 3 (Korshunov et al., 2010). Statistically significant chromosomal aberrations (black boxes) are also displayed between both subgroups,
calculated by Fisher’s exact test.
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and progression-free survival (Table 2) in patients with PF epen-
dymoma. In datasets that do not account for PF molecular
subgroup, extent of resection is the most prognostic variable.
After accounting for PF subgroup, extent of resection is no
longer prognostic for overall survival and has a lower influence
on progression-free survival prediction (Table 2) compared
with an analysis that does not include subgroup assignment
(Table S5). Although these data will need to be repeated and vali-
dated in the setting of a prospective clinical trial, the midline
location, lack of cerebellar invasion, and older age at diagnosis
(B) Median averaged frequencies of DNA copy-number alterations of 45 Group A and 30 PF Group B tumors plotted against their chromosomal position.
See also Figure S3.
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Figure 4. Gene Set Enrichment Analysis Delineates Biological Pathways and Processes that Define Two Distinct Variants of Posterior
Fossa Ependymoma
Gene Set Enrichment Analysis (GSEA) comparing Group A (red) against Group B (blue) PF ependymoma in the Toronto dataset, illustrating distinct pathways and
biological processes between both subgroups (3.5% FDR, p = 0.01). Cytoscape and Enrichment Map were used for visualization of the GSEA results. Nodes
represent enriched gene sets, which are grouped and annotated by their similarity according to related gene sets. Enrichment results were mapped as a network
of gene sets (nodes). Node size is proportional to the total number of genes within each gene set. Proportion of shared genes between gene sets is represented as
the thickness of the green line between nodes. This network map was manually curated removing general and uninformative sub-networks, resulting in
a simplified network map shown in Figure 4. Fully detailed Toronto and Heidelberg network maps are illustrated in Figure S4, and GSEA results can be found in
Table S2.
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in Group B tumors likely lead to a higher incidence of gross total
resection, and some of the prognostic effects noted in prior
publications for gross total resection are likely a surrogate
marker for Group B, as opposed to the more difficult-to-resect
Group A tumors, which are invasive and located laterally in the
cerebellopontine angle of infants.
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Figure 5. Selection and Optimization of PF Ependymoma Group A- and Group B-Specific IHC Markers
(A) Subgroup-specific expression patterns of selected markers, LAMA2 and NELL2, illustrated by heatmaps in both datasets. Candidate genes were identified
using the Goeman’s global test, which assigns a score to each gene based upon its degree of discrimination between defined classes: Group A and Group B.
(B) Box plots derived from mRNA expression data displaying overall differences between markers representing Group A (LAMA2) and Group B (NELL2) in the
Toronto and Heidelberg cohorts. Comparisons were performed using an unpaired t-test.
(C) Representative immunohistochemistry (IHC) staining of LAMA2 and NELL2 on an ependymoma tissuemicroarray (TMA) composed of 265 PF ependymomas.
(D) Pie chart illustrating the distribution of TMA staining for NELL2 and LAMA2. Eight-four percent of posterior fossa ependymomas stain positive for a single
marker.
See also Table S3 and Figure S5.
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DISCUSSION
Our data support the existence of two molecularly distinct
groups of PF ependymoma that, although histologically similar,
differ in their demographic, transcriptional, clinical, and outcome
characteristics. The strength of this hypothesis is supported by
our approach using two non-overlapping cohorts of PF ependy-
momas, studied in two geographic locations, with two distinct
expression array technologies, and then subsequent validation
using an orthogonal technology, on a third independent cohort
of PF ependymomas. Our study of 583 ependymomas repre-
sents the largest cohort of ependymomas analyzed to date.
A prior publication studying a smaller cohort of ependymomas
(29 total tumors) demonstrated that ependymomas from
different regions of the nervous system (supratentorial, posterior
fossa, and spine) had regionally-specific transcriptional profiles
and somatic genetic events, suggesting that ependymomas
from different regions of the nervous system were separate enti-
ties (Taylor et al., 2005). It is noteworthy that in this publication, all
of the supratentorial tumors cluster together, as do all of the
spinal ependymomas. However, the spinal tumors cluster
between two groups of posterior fossa ependymomas, in
keeping with the findings of the current manuscript where
some PF ependymomas (Group B) are more similar to spinal
ependymomas than they are to the other subgroup of PF epen-
dymomas (Group A).
A recent publication described a mouse model of supratento-
rial ependymoma that was generated by transplanting neural
stem cells harboring a combination of deletion of Ink4a/Arf/
and/or overexpression of Ephb2 (Johnson et al., 2010). These
mice developed supratentorial tumors that showed similar
patterns of gene expression and cytogenetic events to 1 of 4
subgroups of supratentorial ependymoma identified from
studying a total of 83 human ependymomas. The same study
also indicated molecular heterogeneity within posterior fossa
tumors, but this aspect was not a focus of the study and no
correlation with clinical outcome was presented for the PF
tumors. Inspection of the subgroups from Johnson et al. reveals
a subgroup that includes both PF and spinal ependymomas, that
is genomically unstable, that includes many adults, (Johnson
et al., subgroup F) and therefore is similar to PF Group B in the
current manuscript. The Johnson et al. study also describes
three subgroups comprised almost exclusively of PF ependymo-
mas (Johnson et al., subgroups G, H, and I), which show few
cytogenetic aberrations other than gain of chromosome 1q,
include a large number of infants, and are therefore similar to
the Group A described in the current manuscript. In line with
previous reports, we conclude that a subset of ependymomas,
labeled in this study as Group A, exhibit a largely balanced chro-
mosomal profile (Johnson et al., 2010; Korshunov et al., 2010;
Mendrzyk et al., 2006; Dyer et al., 2002; Carter et al., 2002).
The high degree of genomic instability in Group B and associa-
tion with an improved prognosis is a paradoxical trend that has
been observed in other neoplasms of the breast, stomach, and
lung (Birkbak et al., 2011).
In our study, chromosome22 losswasoneof themost frequent
genomic alterations, occurring often in Group B PF tumors
and rarely in Group A tumors. Neurofibromin-2 (NF2), located at
chromosome 22q12.2, is thought to be the candidate tumor
suppressor gene of this region because patients with NF2muta-
tions develop numerous neuro-epithelial neoplasms including
spinal ependymoma. However, NF2mutations have been found
exclusively in ependymomasof the spinal cord, highly suggesting
the existence of another chromosome 22q tumor suppressor
gene in the case of PF ependymoma (Ebert et al., 1999).
Examination of molecular pathways characterizing the two PF
ependymoma subgroups revealed two diverse patterns of alter-
ation, again suggesting the existence of two biologically distinct
classes of posterior fossa ependymoma. In Group B ependymo-
mas, only two pathways—ciliogenesis/microtubule assembly
and mitochondrial/oxidative metabolism—were exclusively de-
regulated. A more heterogeneous picture of pathway alteration
was seen in Group A tumors, including several canonical
cancer-associated pathways. Among them were angiogenesis
(HIF-1a signaling, VEGF pathway), PDGF signaling, MAPK
signaling, EGFR signaling, TGF-b signaling, tyrosine-receptor
kinase signaling, RAS signaling, and integrin/ECM signaling.
Molecular research into the pathways driving Groups A and B
may yield targets for subgroup-specific therapy. Because
Group A patients have poor outcome, and because there are
no currently known effective chemotherapeutic regimens in
ependymoma, the therapeutic threshold would be very low in
this underserved patient population. Also, the highly distinct
Groups A and B signaling pathways may also be reflective of
different cells of origin, in keeping with a mechanism that has
recently been shown for supratentorial ependymoma (Johnson
et al., 2010) and for Wnt subgroup medulloblastoma (Gibson
et al., 2010). The transcriptional profiles of Groups A and B pre-
sented in this manuscript will serve as a resource to help guide
future attempts to pinpoint possible alternative cells of origin
that give rise to PF ependymoma.
The most highly differentially expressed genes in Groups A
and B, in both the Toronto and Heidelberg datasets, revealed
candidate marker genes for distinguishing the two groups, the
most striking being upregulation of LAMA2 in Group A and
NELL2 in Group B. Other markers of Group A included previously
reported biomarkers of poor patient outcome including CHI3L1,
TNC, VEGF, EGFR, ERRB4, BIRC5, and S100A6 (Figure S5A)
(Rand et al., 2008; Korshunov et al., 2002; Mendrzyk et al.,
2006; Gilbertson et al., 2002; Preusser et al., 2005). This
evidence, in addition to the lack of prognostic significance for
chromosome 1q gain in Group A patients, suggests that some
previously reported markers of poor outcome may have been
surrogate markers for Group A.
Because Group B ependymomas are much less likely to recur,
metastasize, or result in the death of the patient, validation of our
results in additional cohorts of patients would suggest that
Group B patients could be treated less aggressively than
Group A patients. Conversely, the poor outcome for Group A
patients underlines the need for rapid development of adjuvant
therapies for these patients.
We anticipate that analysis of additional cohorts of posterior
fossa ependymoma will further support the existence of at least
two divergent molecular variants that are demographically,
genetically, transcriptionally, and clinically distinct. The anti-
bodies described for LAMA2 and NELL2 are both commercially
available and therefore should be widely available across the
globe for validation of our results and eventually for use in
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Figure 6. Clinical andCytogenetic CharacteristicsDistinguishing IHC-DefinedGroupA andBSubgroups in a ThirdNonoverlapping Posterior
Fossa Ependymoma Cohort
(A) Comparing subgroup-specific cytogenetic aberrations and risk group classifications (Korshunov et al., 2010) betweenNELL2–/LAMA2+ andNELL2+/LAMA2–
tumors of the TMA validation cohort. The heatmap illustrates the association of cytogenetic risk groups 2 and 3 with NELL2–/LAMA2+ tumors, and cytogenetic
risk group 1 aberrations with NELL2+/LAMA2– tumors. Statistical significance was performed by Fisher’s exact test (n = 155). NELL2+/LAMA2– tumors
show a greater extent of genomic instability as expected from the increased genomic instability seen in Group B tumors in the discovery datasets. Conversely,
NELL2–/LAMA2+ tumors exhibit a more balanced genomic profile, with chromosome 1q gain identified as the only significant chromosomal aberration.
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prognostication and stratification of PF ependymoma patients.
We would also suggest that future clinical trials should prospec-
tively validate IHC staining for LAMA2 and NELL2 on formalin-
fixed, paraffin-embedded tumor material. Importantly, to further
improve our understanding of the molecular biology of these
posterior fossa subgroups, prospective investigations into the
cell-of-origin and genetic driver mutations are desperately
needed, including modeling of PF ependymoma in the mouse.
Finally, the distinct molecular characteristics of these two groups
of PF ependymoma suggest that subgroup-specific targeted
therapies against subgroup-specific deregulated pathways are
needed in future treatments of these tumors.
EXPERIMENTAL PROCEDURES
Patients and Tumor Samples
Clinical samples and data were used in accordance with research ethics board
approval from both The Hospital of Sick Children (Toronto, Ontario) and DKFZ
(Heidelberg, Germany). Informed consent was obtained from all patients in this
study. Detailed patient and sample information for all three cohorts can be
found in the supplemental experimental procedures, and also in Table S1
and Table S3.
Gene Expression Array Processing
One-hundred-two Toronto ependymoma samples were analyzed on the
Affymetrix Human Exon 1.0 ST Gene Chip at the London Regional Genomics
Centre (London, Ontario). Sample library preparation, hybridization, and
quality control were performed according to Affymetrix recommended proto-
cols. CEL files were imported into Affymetrix Expression Console (Version 1.1)
and gene level analysis (CORE content) was performed. Arrays were quantile
normalized (sketch) and summarized using PLIERwith PM-GCBGbackground
correction. Probesets were annotated according to the human genome build
HG19 (GRCh37).
RNA isolated from 75 ependymomas of the Heidelberg cohort was pro-
cessed and hybridized to the 4x44K feature Agilent Whole Human Genome
Oligo Microarray according to the manufacturer’s instructions. All hybridiza-
tion experiments were investigated by labeling tumor sample against refer-
ence probes normal brain pool, and scanned in a two-color Agilent Scanner
G25505B according to the manufacturer’s specification. Array raw data
were generated from scanned images using Feature Extraction 9.1 Software
(Agilent). Pre-processing of the data and quality control were conducted
with our in-house developed ChipYard framework for microarray data analysis
(http://www.dkfz.de/genetics/ChipYard/) using R statistical software and
Bioconductor (Gentleman et al., 2004) packages. Normalization of raw signals
was performed using vsn (Huber et al., 2002).
Array-Comparative Genomic Hybridization
Array-CGH (Solinas-Toldo et al., 1997) at an average probe spacing of 0.4 Mb
was carried out as previously described (Korshunov et al., 2010) for the
Heidelberg and Toronto datasets. Microarray data analysis was performed
as previously reported (Zielinski et al., 2005).
Statistical Analysis of Gene Expression–Based Subgroups
Missing values in the Agilent gene expression dataset were imputed using
k-nearestneighboralgorithm(Reichetal., 2006). Inbothdatasets, duplicatepro-
besetswere filtered to the highest variant probesets acrossall samples. ForHCL
consensus clustering, datasets were reduced to 1000 probesets exhibiting the
largest median absolute deviation (MAD). For NMF consensus clustering, data-
sets were reduced to 5000 probesets exhibiting the largest MAD scores.
Identification of Gene Expression–Derived Subgroups
To detect robust sample clusters, we used hierarchical clusteringwith agglom-
erative average linkage as our method for consensus clustering (R package:
ConsensusClusterPlus; Wilkerson and Hayes, 2010). Datasets were median-
centered and the distance measure was computed as 1 minus the Pearson’s
correlation coefficient. Clustering was performed over 1000 iterations at a sub-
sampling ratio of 0.8. SigClust was used to compute significance tests on the
identified clusters in a pairwise fashion (R package: sigclust; Liu et al., 2008).
Silhouette analysis was performed to identify ‘‘core’’ samples (R package:
cluster; Rousseeuw, 1987). Only members with a positive silhouette value
were retained for further analysis as highly representative samples of their
subgroup assignment. Subclass mapping using the SubMap module (version
3), within GenePattern software, was performed to determine the commonality
of the subtypes identified in the two datasets (Hoshida et al., 2007; Reich et al.,
2006). Consensus NMF was used to assess the sample memberships at a
3-subgroup classification. NMF (R package: NMF version 0.5.02) was per-
formed on each dataset for 1000 resampling iterations using the parameters
(B–G) Comparing subgroup-specific demographic and clinical information in the validation cohort illustrated by:
(B) Box plots for age indicating that NELL2–/LAMA2+ tumors represent a significantly younger population than NELL2+/LAMA2 tumors;
(C and D) Bar graphs demonstrating that NELL2–/LAMA2+ tumors are over-represented by males and WHO Grade III tumors;
(E–G) Kaplan-Meier plots demonstrate that NELL2–/LAMA2+ tumors have an earlier time to metastasis and have a poorer progression-free and overall survival
than NELL2+/LAMA2– tumors. Statistical significance of age was determined by a Mann-Whitney U test, gender and grade by a Fisher’s exact test, and time to
metastasis and survival by a log-rank test.
(H and I) Limiting to gross-totally resected cases, Kaplan-Meier curves demonstrating that NELL2–/LAMA2+ tumors have a significantly poorer survival than
NELL2+/LAMA2– tumors. Statistical significance was determined by a log-rank test.
See also Table S4 and Figure S6.
Table 2. Cox Proportional Hazards Models for Overall Survival
and Progression-Free Survival of Posterior Fossa Ependymoma
of TMA Validation Cohort
Variable
Hazard
Ratio 95% CI P valuea
Overall Survival
Gender (male versus female) 1.42 0.67-3.04 0.3591
Resection (GTR versus STR) 0.66 0.32-1.34 0.2470
Age, years (4-18 versus <4) 1.81 0.77-4.25 0.1746
Histology (grade 3 versus grade 2) 1.92 0.79-4.68 0.1486
Age, years (>18 versus <4) 0.44 0.16-1.24 0.1202
Radiotherapy (yes versus no) 0.29 0.11-0.77 0.0135
NELL2 (positive versus negative) 0.12 0.03-0.44 0.0012
LAMA2 (positive versus negative) 10.55 2.81-39.60 0.0005
Progression-Free Survival
Gender (male versus female) 1.17 0.74-1.85 0.5037
Radiotherapy (yes versus no) 0.80 0.44-1.47 0.4744
Age, years (4-18 versus <4) 0.68 0.34-1.35 0.2686
Histology (grade 3 versus grade 2) 1.42 0.79-2.57 0.2423
Age, years (>18 versus <4) 1.80 0.99-3.27 0.0535
Resection (GTR versus STR) 0.53 0.34-0.83 0.0061
NELL2 (positive versus negative) 0.32 0.17-0.61 0.0005
LAMA2 (positive versus negative) 8.45 4.08-17.49 <0.0001
No. of patients with fossa posterior ependymoma = 265; CI, confidence
interval.
aWald Test.
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described previously (Brunet et al., 2004). Sample memberships were then
compared against the HCL analysis using a Rand index. The significance of
the Rand index was assessed by permutation of the Toronto sample labels
and computing the Rand index over 10,000 iterations to generate a null
distribution of Rand index values.
Principal component analysis was performed within Partek Genomics Suite
(Partek Inc., St. Louis, MO) to compare Group A and Group B posterior fossa
subtypes with the same 1000 genes used for consensus HCL. Both groups
were highlighted by their HCL cluster membership and encircled by ellipsoids
measuring two standard deviations around the center of each subgroup.
Identification of Biological Pathways Distinguishing Group A
from Group B Posterior Fossa Ependymomas
Gene Set Enrichment Analysis (Subramanian et al., 2005), as visualized in
Cytoscape (version 2.7.0), and the Enrichment Map software (Merico et al.,
2010), were used to identify the biological processes discriminating Group A
from Group B ependymomas. Gene sets were compiled from NCI, KEGG,
PFAM, Biocarta, and GO databases. Using the Toronto dataset, GSEA anal-
ysis was performed using gene-set permutations with a FDR cutoff of 3.5%
and p-value cutoff of 0.01. The network map was manually curated removing
general and uninformative sub-networks and nodes, resulting in a simplified
network map shown in Figure 4. The complete network map for the Toronto
dataset can be found in Figure S4A. Because of differences in microarray
platforms, different GSEA parameters were needed to generate the network
map comparing Group A and Group B in the dataset from Heidelberg (Fig-
ure S4B; FDR < 0.10, p < 0.01). GSEA results for both Toronto and Heidelberg
datasets can be found in Table S2.
Selection of Candidate Genes and Gene Signatures
We computed the test statistic of Goeman’s global test for logistic regression
to derive the contributions made by each of the genes on discriminating
between the two groups (Goeman et al., 2004). Individual transcripts were
then ranked by their influence. Finally, we selected 100 candidate genes
with highest ranks in both datasets as representative subgroup markers for
Group A and Group B.
Statistical Analysis of Clinical Parameters
Estimation of survival time distribution was performed by themethod of Kaplan
and Meier. For comparisons of two or more survival curves, the log-rank test
was used. Comparisons of binary and categorical patient characteristics
between age groups were performed by use of a two-sided Fisher’s exact
test. Tumor removal was evaluated on the post-operative MRI as either gross
total resection (no visible tumor) or subtotal resection (visible tumor remaining).
To evaluate the status of recurrence, metastasis at recurrence, and mortality
5 years after diagnosis, we selected patients with a 5-year follow-up in the
expression cohort. Wilcoxon rank-sum test was used to perform two-sample
location tests for at least ordinal covariates. Multivariate Cox regression
analysis was used to evaluate the impact of subgroup markers together with
prognostically relevant clinical and histopathological factors. The result of
a test was always judged as statistically significant when the corresponding
two-sided p-value was less than 0.05. The prognostic value of clinical and
molecular factors was assessed by their estimated hazard ratios including
95% confidence intervals. Box-and-whisker plots illustrate numerical data
represented in numbers for five variables: minimum value, lower quartile,
median, upper quartile, and maximum value.
ACCESSION NUMBERS
Gene expression and aCGH data for both Toronto (GSE27279) and Heidelberg
(GSE27287) datasets can be found at the NCBI Gene Expression Omnibus
repository.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, five tables, and Supplemental
Experimental Procedures and can be found with this article online at
doi:10.1016/j.ccr.2011.07.007.
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